ArticleDiscover oncology2026
Modulation of breast cancer progression in high-altitude hypoxia by Tongqiaohuoxue Decoction via HIF-1α/VEGF signaling.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTo explore the therapeutic efficacy and underlying mechanisms of Tongqiao Huoxue Decoction (THD) in the context of breast cancer development under high-altitude hypoxic conditions.
methodsWe established an in vivo breast cancer hypoxia model and utilized a small animal in vivo imaging system for oncological investigation. Routine blood tests and coagulation profile tests were conducted to assess platelet count and coagulation function. Pathological changes in tumor tissues were observed. Immunohistochemistry (IHC) was employed to detect positive rates of hypoxia inducible factor (HIF)-1α, P-selectin (CD62P), platelet-derived growth factor receptor (PDGFR), vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (BFGF) in tumor tissues. Western blotting was used to evaluate protein expression levels of HIF-1α, VEGF, cellular myelocytomatosis oncogene (c-MYC), and platelet-derived growth factor receptor β (PDGFR-β).
resultsUnder hypoxic conditions, orthotopic tumor volume and weight, and the number and area of lung metastases significantly increased. Platelet count increased, and prothrombin time was prolonged. IHC and immunoblot analyses revealed that HIF-1α, VEGF, and PDGFR-β expression were upregulated under hypoxia. Following THD treatment, the volume and weight of orthotopic tumors decreased, and so did the number and area percentage of lung metastases. Platelet and D-dimer counts decreased, while activated partial thromboplastin time and thrombin time were prolonged. Protein expression levels of HIF-1α, VEGF, c-MYC, and PDGFR-β were downregulated.
conclusionBased on the current data, the ameliorative effects of THD on tumor hypoxia and hypercoagulability under high-altitude conditions may be associated with the modulation of the HIF-1α/VEGF signaling pathway, providing clues to its potential mechanisms for suppressing tumor growth, metastasis, and angiogenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.